Back to top

Analyst Blog

Endo Health Solutions (ENDP - Analyst Report) recently issued a disappointing outlook for 2013. The US-based diversified healthcare company expects adjusted earnings per share for 2013 in the range of $4.40 -$4.70 per share. The guidance range is significantly below the Zacks Consensus Estimate of $5.02 per share.

The company expects to end 2013 with revenues in the range of $2.80 - $2.95 billion, again below the Zacks Consensus Estimate of $3.1 billion. We believe that the entry of a generic competitor, Watson Pharma , for Endo Health’s lead drug Lidoderm in September 2013 is primarily responsible for the disappointing 2013 guidance. Moreover, the 2013 outlook also assumes generic competition for Endo Health’s key pain drug Opana ER. Consequently, Opana ER’s sales for 2013 are expected to be 20% less on a year-over-year basis.

We remind investors that Endo Health had earlier forecasted 2013 adjusted earnings in the range of $5.20-$5.40 per share on revenues of $3.0 - $3.2 billion. The company withdrew the projection last month and issued the fresh guidance in January 2013.

Apart from issuing 2013 outlook, the company also maintained its view for 2012. The company continues to expect adjusted earnings for 2012 at or below the low end of the forecasted range of $5.00-$5.10 per share. The Zacks Consensus Estimate for 2012 is currently pegged at $4.99 per share. The company expects to unveil its financial results for fourth quarter and full year 2012 by the end of next month.

We have a Neutral recommendation on Endo Health. The stock carries a Zacks #3 Rank (Hold) in the short run. Health care stocks that carry a Zacks #2 Rank (Buy) include Allergan, Inc. (AGN - Analyst Report).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%